Survival Outcomes of Metastatic Colorectal Cancer (mCRC) in A Single Practice Cohort in Medellín, Colombia
La terapia para CCRm consiste en cirugía, quimioterapia citotóxica y agentes biológicos. En los ensayos clínicos aleatorizados, la mediana de supervivencia libre de progresión (SLP) y supervivencia global (SG) ronda los 10 y 29 meses, respectivamente. No existen publicaciones sobre los resultados de supervivencia en CCRM en Colombia. Objetivo: Describir los resultados de supervivencia de pacientes con CCRm tratados por Mauricio Lema, Medellín, Colombia. Métodos: Serie de casos retrospectiva (2008-2020) de CCRm, ≥18 años, tratados con terapia sistémica para la enfermedad metastásica y seguimiento ≥3 meses. Los factores de estratificación incluyeron: uso de biológico (anti VEGF/anti EGFR) más quimioterapia en 1ª línea (sí/no) y metastasectomí... Ver más
Guardado en:
2256-2877
2256-2915
8
2021-10-01
18
28
info:eu-repo/semantics/openAccess
http://purl.org/coar/access_right/c_abf2
Revista Colombiana de Hematología y Oncología - 2021
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
| id |
0c61424b274441e899f76eba11f5a044 |
|---|---|
| record_format |
ojs |
| spelling |
Survival Outcomes of Metastatic Colorectal Cancer (mCRC) in A Single Practice Cohort in Medellín, Colombia metástasis de la neoplasia Revista Colombiana de Hematología y Oncología Asociación Colombiana de Hematología y Oncología (ACHO) Artículo de revista Núm. 1 , Año 2021 : Enero-Junio 1 análisis de supervivencia bevacizumab terapia biológica 8 Neoplasias del colon Preciado Franco, Beatriz Elena Ríos Fergusson, Mónica Patricia Mora Vélez, Sara Paulina Romero Millán, Ana María Quiceno Pareja, Diana Marcela La terapia para CCRm consiste en cirugía, quimioterapia citotóxica y agentes biológicos. En los ensayos clínicos aleatorizados, la mediana de supervivencia libre de progresión (SLP) y supervivencia global (SG) ronda los 10 y 29 meses, respectivamente. No existen publicaciones sobre los resultados de supervivencia en CCRM en Colombia. Objetivo: Describir los resultados de supervivencia de pacientes con CCRm tratados por Mauricio Lema, Medellín, Colombia. Métodos: Serie de casos retrospectiva (2008-2020) de CCRm, ≥18 años, tratados con terapia sistémica para la enfermedad metastásica y seguimiento ≥3 meses. Los factores de estratificación incluyeron: uso de biológico (anti VEGF/anti EGFR) más quimioterapia en 1ª línea (sí/no) y metastasectomía (sí/no). Se realizó análisis de supervivencia con Kaplan-Meier. Se describen los resultados discriminados por el uso de un agente biológico en la primera línea de tratamiento. Resultados: Se incluyeron 89 pacientes con CCRm. Mediana de seguimiento: 35 meses (RIQ: 21-57). Mediana de SLP fue 12,1 meses (IC95%: 10,4-13,8) y SG fue 29,3 meses (IC95%: 23,2-34,4). La mediana de SG en quienes recibieron biológicos fue 28,8 meses (IC95%: 22,1-35,6) frente a 33,7 meses (IC95%: 16,4-51,0) en el grupo de quimioterapia sola (p = 0,01). La mediana de SG en los grupos con metastasectomía, y sin metastasectomía fue de 36,1 (IC95%: 26,5-45,7), y 25,0 meses (IC95%: 15,4-34,5) respectivamente (NS). Conclusión: Los resultados de supervivencia fueron similares a los informados en grandes ensayos de fase III. El tamaño de la muestra excluye cualquier conclusión sobre el impacto de los agentes biológicos en la supervivencia en este estudio. Lema , Mauricio Lema, Camila Uribe C, Osma S, Herrera V. Cancer incidence and mortality in the Bucaramanga metropolitan area, 2003-2007. Colomb Med. 2012;43(4):290–7. Available from: https://doi.org/10.25100/cm.v43i4.1196. Bohorquez M, Sahasrabudhe R, Criollo A, Sanabria-Salas MC, Vélez A, Castro JM, et al. Clinical manifestations of colorectal cancer patients from a large multicenter study in Colombia. Med (United States). 2016;95(40). Available from: https://doi.org/10.1097/MD.0000000000004883. Cortés A, Eduardo Bravo L, Stella García L, Collazos P. Incidencia, mortalidad y supervivencia por cáncer colorrectal en Cali, Colombia, 1962-2012. (Spanish). Color cancer Incid Mortal Surviv Cali, Colomb 1962-2012 [Internet]. 2014;56(5):457–64. Available from: http://search.ebscohost.com/login.aspx?direct=true&db=bth&AN=98909692&lang=es&site=ehost-live. Liu Z, Zhang L, Xu X, Pan Y, Chen D, Liu D, et al. Current status of immunotherapy for metastatic colorectal cancer. Cancer Res Prev Treat. 2020;47(12):925–30. Available from: https://doi.org/10.3971/j.issn.1000-8578.2020.20.0864. Chakedis J, Schmidt CR. Surgical Treatment of Metastatic Colorectal Cancer. Surg Oncol Clin N Am [Internet]. 2018;27(2):377–99. Available from: https://doi.org/10.1016/j.soc.2017.11.010 Stein A, Folprecht G. Immunotherapy of Colon Cancer. Oncol Res Treat. 2018;41(5):282–5. Available from: https://doi.org/10.1159/000488918. Ciombor KK, Bekaii‐Saab T. A Comprehensive Review of Sequencing and Combination Strategies of Targeted Agents in Metastatic Colorectal Cancer. Oncologist. 2018;23(1):25–34. Available from: https://doi.org/ 10.1634/theoncologist.2017-0203. Campo-Sánchez SM, Camargo-Trillos J, Calle-Ramírez JA, Gómez-Wolff LR, Sánchez-Patiño LA, García-García HI. Colorectal cancer survival at an oncologic center in Colombia. A historic cohort study. Rev Gastroenterol Mex. 2019;84(2):174–84. Available from: https://doi.org/10.1016/j.rgmx.2018.04.002. Fakih MG. Metastatic colorectal cancer: Current state and future directions. J Clin Oncol. 2015;33(16):1809–24. Available from: https://doi.org/10.1200/JCO.2014.59.7633 Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, Fruth B, Meyerhardt JA, et al. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer a randomized clinical trial. JAMA - J Am Med Assoc. 2017;317(23):2392–401. Available from: https://doi.org/10.1001/jama.2017.7105. Aderka D, Stintzing S, Heinemann V. Explaining the unexplainable: discrepancies in results from the CALGB/SWOG 80405 and FIRE-3 studies. Lancet Oncol [Internet]. 2019;20(5):e274–83. Available from: http://dx.doi.org/10.1016/S1470-2045(19)30172-X. Text Heinemann V, Weikersthal LF Von, Decker T, Kiani A, Vehling-kaiser U, Scholz M, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): A randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15(10):1065–75. Available from: https://doi.org/10.1016/S1470-2045(14)70330-4. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): Long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2013;14(12):1208–15. Available from: https://doi.org/10.1016/S1470-2045(13)70447-9. info:eu-repo/semantics/article http://purl.org/coar/resource_type/c_6501 Arnold M, Abnet CC, Neale RE, Vignat J, Giovannucci EL, McGlynn KA, et al. Global Burden of 5 Major Types of Gastrointestinal Cancer. Gastroenterology [Internet]. 2020;159(1):335-349.e15. Available from: https://doi.org/10.1053/j.gastro.2020.02.068 http://purl.org/redcol/resource_type/ARTREF info:eu-repo/semantics/publishedVersion http://purl.org/coar/version/c_970fb48d4fbd8a85 info:eu-repo/semantics/openAccess http://purl.org/coar/access_right/c_abf2 International Agency for Research on Cancer. GLOBOCAN 2020: Estimated cancer incidence, mortality and prevalence worldwide in 2020 [Internet]. 2020. Available from: https://gco.iarc.fr/today/home Publication Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66(4):683–91. Available from: https://doi.org/10.1136/gutjnl-2015-310912. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;0(0):1–41. Available from: https://doi.org/10.3322/caac.21660. Therapy for mCRC is based on surgery, cytotoxic chemotherapy, and biologic agents. In randomized clinical trials, median progression-free survival (PFS) and overall survival (OS) hover around 10mo and 29mo, respectively. There are no published results on survival outcomes of patients with mCRC in Colombia. Objective: Describe the survival outcomes of patients with mCRC treated by Mauricio Lema in Medellín, Colombia. Methods: This is a retrospective, case series (2008-2020) of mCRC, ≥18 years old, treated with systemic therapy for metastatic disease, and ≥3-month follow-up. Stratification factors included: use of biologic (anti-VEGF or anti-EGFR) plus chemotherapy in 1st-Line (yes/no) and metastasectomy (yes/no). Survival analyses were evaluated using Kaplan- Meier curves. Results from the general population are described, and they are also discriminated against by the use of a biological agent in the first-line of systemic therapy. Results: 89 patients with mCRC were included. The Median follow-up was 35 months (IQR: 21-57). Median PFS and OS were 12.1mo (95%CI: 10.4-13.8) and 29.3mo (95%CI: 23.2-34.4), respectively. Median OS in patients receiving biologics was 28.8mo (95%CI: 22.1 – 35.6) vs 33.7mo (95%CI: 16.4 – 51.0) in the chemo-only group (p=0.01). Median OS in the metastasectomy and non-metastasectomy groups were 36.1 (95% CI: 26.5 - 45.7) and 25.0 months (95% CI: 15.4 - 34.5), respectively (NS). Conclusion: In this case series of patients’ survival outcomes were similar to thosereported in large phase III trials. A small sample size precludes any conclusion as to the impact of biologic agents on survival in this study. Colonic neoplasms neoplasm metastasis biological therapy bevacizumab survival analysis Journal article application/pdf https://revista.acho.info/index.php/acho/article/view/375 Resultados de supervivencia del cáncer colorrectal metastásico (CCRm) en una cohorte de una práctica en Medellín, Colombia Inglés https://creativecommons.org/licenses/by-nc-nd/4.0 Revista Colombiana de Hematología y Oncología - 2021 Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0. 2256-2915 2256-2877 2021-10-01 2021-10-01T19:10:11Z https://revista.acho.info/index.php/acho/article/download/375/361 2021-10-01T19:10:11Z https://doi.org/10.51643/22562915.375 18 28 10.51643/22562915.375 |
| institution |
ASOCIACION COLOMBIANA DE HEMATOLOGIA Y ONCOLOGIA |
| thumbnail |
https://nuevo.metarevistas.org/ASOCIACIONCOLOMBIANADEHEMATOLOGIAYONCOLOGIA/logo.png |
| country_str |
Colombia |
| collection |
Revista Colombiana de Hematología y Oncología |
| title |
Survival Outcomes of Metastatic Colorectal Cancer (mCRC) in A Single Practice Cohort in Medellín, Colombia |
| spellingShingle |
Survival Outcomes of Metastatic Colorectal Cancer (mCRC) in A Single Practice Cohort in Medellín, Colombia Preciado Franco, Beatriz Elena Ríos Fergusson, Mónica Patricia Mora Vélez, Sara Paulina Romero Millán, Ana María Quiceno Pareja, Diana Marcela Lema , Mauricio Lema, Camila metástasis de la neoplasia análisis de supervivencia bevacizumab terapia biológica Neoplasias del colon Colonic neoplasms neoplasm metastasis biological therapy bevacizumab survival analysis |
| title_short |
Survival Outcomes of Metastatic Colorectal Cancer (mCRC) in A Single Practice Cohort in Medellín, Colombia |
| title_full |
Survival Outcomes of Metastatic Colorectal Cancer (mCRC) in A Single Practice Cohort in Medellín, Colombia |
| title_fullStr |
Survival Outcomes of Metastatic Colorectal Cancer (mCRC) in A Single Practice Cohort in Medellín, Colombia |
| title_full_unstemmed |
Survival Outcomes of Metastatic Colorectal Cancer (mCRC) in A Single Practice Cohort in Medellín, Colombia |
| title_sort |
survival outcomes of metastatic colorectal cancer (mcrc) in a single practice cohort in medellín, colombia |
| title_eng |
Resultados de supervivencia del cáncer colorrectal metastásico (CCRm) en una cohorte de una práctica en Medellín, Colombia |
| description |
La terapia para CCRm consiste en cirugía, quimioterapia citotóxica y agentes biológicos. En los ensayos clínicos aleatorizados, la mediana de supervivencia libre de progresión (SLP) y supervivencia global (SG) ronda los 10 y 29 meses, respectivamente. No existen publicaciones sobre los resultados de supervivencia en CCRM en Colombia. Objetivo: Describir los resultados de supervivencia de pacientes con CCRm tratados por Mauricio Lema, Medellín, Colombia. Métodos: Serie de casos retrospectiva (2008-2020) de CCRm, ≥18 años, tratados con terapia sistémica para la enfermedad metastásica y seguimiento ≥3 meses. Los factores de estratificación incluyeron: uso de biológico (anti VEGF/anti EGFR) más quimioterapia en 1ª línea (sí/no) y metastasectomía (sí/no). Se realizó análisis de supervivencia con Kaplan-Meier. Se describen los resultados discriminados por el uso de un agente biológico en la primera línea de tratamiento. Resultados: Se incluyeron 89 pacientes con CCRm. Mediana de seguimiento: 35 meses (RIQ: 21-57). Mediana de SLP fue 12,1 meses (IC95%: 10,4-13,8) y SG fue 29,3 meses (IC95%: 23,2-34,4). La mediana de SG en quienes recibieron biológicos fue 28,8 meses (IC95%: 22,1-35,6) frente a 33,7 meses (IC95%: 16,4-51,0) en el grupo de quimioterapia sola (p = 0,01). La mediana de SG en los grupos con metastasectomía, y sin metastasectomía fue de 36,1 (IC95%: 26,5-45,7), y 25,0 meses (IC95%: 15,4-34,5) respectivamente (NS). Conclusión: Los resultados de supervivencia fueron similares a los informados en grandes ensayos de fase III. El tamaño de la muestra excluye cualquier conclusión sobre el impacto de los agentes biológicos en la supervivencia en este estudio.
|
| description_eng |
Therapy for mCRC is based on surgery, cytotoxic chemotherapy, and biologic agents. In randomized clinical trials, median progression-free survival (PFS) and overall survival (OS) hover around 10mo and 29mo, respectively. There are no published results on survival outcomes of patients with mCRC in Colombia. Objective: Describe the survival outcomes of patients with mCRC treated by Mauricio Lema in Medellín, Colombia. Methods: This is a retrospective, case series (2008-2020) of mCRC, ≥18 years old, treated with systemic therapy for metastatic disease, and ≥3-month follow-up. Stratification factors included: use of biologic (anti-VEGF or anti-EGFR) plus chemotherapy in 1st-Line (yes/no) and metastasectomy (yes/no). Survival analyses were evaluated using Kaplan- Meier curves. Results from the general population are described, and they are also discriminated against by the use of a biological agent in the first-line of systemic therapy. Results: 89 patients with mCRC were included. The Median follow-up was 35 months (IQR: 21-57). Median PFS and OS were 12.1mo (95%CI: 10.4-13.8) and 29.3mo (95%CI: 23.2-34.4), respectively. Median OS in patients receiving biologics was 28.8mo (95%CI: 22.1 – 35.6) vs 33.7mo (95%CI: 16.4 – 51.0) in the chemo-only group (p=0.01). Median OS in the metastasectomy and non-metastasectomy groups were 36.1 (95% CI: 26.5 - 45.7) and 25.0 months (95% CI: 15.4 - 34.5), respectively (NS). Conclusion: In this case series of patients’ survival outcomes were similar to thosereported in large phase III trials. A small sample size precludes any conclusion as to the impact of biologic agents on survival in this study.
|
| author |
Preciado Franco, Beatriz Elena Ríos Fergusson, Mónica Patricia Mora Vélez, Sara Paulina Romero Millán, Ana María Quiceno Pareja, Diana Marcela Lema , Mauricio Lema, Camila |
| author_facet |
Preciado Franco, Beatriz Elena Ríos Fergusson, Mónica Patricia Mora Vélez, Sara Paulina Romero Millán, Ana María Quiceno Pareja, Diana Marcela Lema , Mauricio Lema, Camila |
| topicspa_str_mv |
metástasis de la neoplasia análisis de supervivencia bevacizumab terapia biológica Neoplasias del colon |
| topic |
metástasis de la neoplasia análisis de supervivencia bevacizumab terapia biológica Neoplasias del colon Colonic neoplasms neoplasm metastasis biological therapy bevacizumab survival analysis |
| topic_facet |
metástasis de la neoplasia análisis de supervivencia bevacizumab terapia biológica Neoplasias del colon Colonic neoplasms neoplasm metastasis biological therapy bevacizumab survival analysis |
| citationvolume |
8 |
| citationissue |
1 |
| citationedition |
Núm. 1 , Año 2021 : Enero-Junio |
| publisher |
Asociación Colombiana de Hematología y Oncología (ACHO) |
| ispartofjournal |
Revista Colombiana de Hematología y Oncología |
| source |
https://revista.acho.info/index.php/acho/article/view/375 |
| language |
Inglés |
| format |
Article |
| rights |
info:eu-repo/semantics/openAccess http://purl.org/coar/access_right/c_abf2 https://creativecommons.org/licenses/by-nc-nd/4.0 Revista Colombiana de Hematología y Oncología - 2021 Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0. |
| references_eng |
Uribe C, Osma S, Herrera V. Cancer incidence and mortality in the Bucaramanga metropolitan area, 2003-2007. Colomb Med. 2012;43(4):290–7. Available from: https://doi.org/10.25100/cm.v43i4.1196. Bohorquez M, Sahasrabudhe R, Criollo A, Sanabria-Salas MC, Vélez A, Castro JM, et al. Clinical manifestations of colorectal cancer patients from a large multicenter study in Colombia. Med (United States). 2016;95(40). Available from: https://doi.org/10.1097/MD.0000000000004883. Cortés A, Eduardo Bravo L, Stella García L, Collazos P. Incidencia, mortalidad y supervivencia por cáncer colorrectal en Cali, Colombia, 1962-2012. (Spanish). Color cancer Incid Mortal Surviv Cali, Colomb 1962-2012 [Internet]. 2014;56(5):457–64. Available from: http://search.ebscohost.com/login.aspx?direct=true&db=bth&AN=98909692&lang=es&site=ehost-live. Liu Z, Zhang L, Xu X, Pan Y, Chen D, Liu D, et al. Current status of immunotherapy for metastatic colorectal cancer. Cancer Res Prev Treat. 2020;47(12):925–30. Available from: https://doi.org/10.3971/j.issn.1000-8578.2020.20.0864. Chakedis J, Schmidt CR. Surgical Treatment of Metastatic Colorectal Cancer. Surg Oncol Clin N Am [Internet]. 2018;27(2):377–99. Available from: https://doi.org/10.1016/j.soc.2017.11.010 Stein A, Folprecht G. Immunotherapy of Colon Cancer. Oncol Res Treat. 2018;41(5):282–5. Available from: https://doi.org/10.1159/000488918. Ciombor KK, Bekaii‐Saab T. A Comprehensive Review of Sequencing and Combination Strategies of Targeted Agents in Metastatic Colorectal Cancer. Oncologist. 2018;23(1):25–34. Available from: https://doi.org/ 10.1634/theoncologist.2017-0203. Campo-Sánchez SM, Camargo-Trillos J, Calle-Ramírez JA, Gómez-Wolff LR, Sánchez-Patiño LA, García-García HI. Colorectal cancer survival at an oncologic center in Colombia. A historic cohort study. Rev Gastroenterol Mex. 2019;84(2):174–84. Available from: https://doi.org/10.1016/j.rgmx.2018.04.002. Fakih MG. Metastatic colorectal cancer: Current state and future directions. J Clin Oncol. 2015;33(16):1809–24. Available from: https://doi.org/10.1200/JCO.2014.59.7633 Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, Fruth B, Meyerhardt JA, et al. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer a randomized clinical trial. JAMA - J Am Med Assoc. 2017;317(23):2392–401. Available from: https://doi.org/10.1001/jama.2017.7105. Aderka D, Stintzing S, Heinemann V. Explaining the unexplainable: discrepancies in results from the CALGB/SWOG 80405 and FIRE-3 studies. Lancet Oncol [Internet]. 2019;20(5):e274–83. Available from: http://dx.doi.org/10.1016/S1470-2045(19)30172-X. Heinemann V, Weikersthal LF Von, Decker T, Kiani A, Vehling-kaiser U, Scholz M, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): A randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15(10):1065–75. Available from: https://doi.org/10.1016/S1470-2045(14)70330-4. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): Long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2013;14(12):1208–15. Available from: https://doi.org/10.1016/S1470-2045(13)70447-9. Arnold M, Abnet CC, Neale RE, Vignat J, Giovannucci EL, McGlynn KA, et al. Global Burden of 5 Major Types of Gastrointestinal Cancer. Gastroenterology [Internet]. 2020;159(1):335-349.e15. Available from: https://doi.org/10.1053/j.gastro.2020.02.068 International Agency for Research on Cancer. GLOBOCAN 2020: Estimated cancer incidence, mortality and prevalence worldwide in 2020 [Internet]. 2020. Available from: https://gco.iarc.fr/today/home Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66(4):683–91. Available from: https://doi.org/10.1136/gutjnl-2015-310912. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;0(0):1–41. Available from: https://doi.org/10.3322/caac.21660. |
| type_driver |
info:eu-repo/semantics/article |
| type_coar |
http://purl.org/coar/resource_type/c_6501 |
| type_version |
info:eu-repo/semantics/publishedVersion |
| type_coarversion |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| type_content |
Text |
| publishDate |
2021-10-01 |
| date_accessioned |
2021-10-01T19:10:11Z |
| date_available |
2021-10-01T19:10:11Z |
| url |
https://revista.acho.info/index.php/acho/article/view/375 |
| url_doi |
https://doi.org/10.51643/22562915.375 |
| issn |
2256-2877 |
| eissn |
2256-2915 |
| doi |
10.51643/22562915.375 |
| citationstartpage |
18 |
| citationendpage |
28 |
| url2_str_mv |
https://revista.acho.info/index.php/acho/article/download/375/361 |
| _version_ |
1797159781964709888 |